By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 10 November 2026
Mounjaro is the newest addition to the weight-loss injections – and the most effective one in the studies to date. The difference: while Ozempic and Wegovy mimic a single hormone, Mounjaro activates two distinct signalling pathways at the same time.
What that means medically, how the dosing schedule is structured and where Mounjaro stands in direct comparisons – all of that is covered here.
Mounjaro contains the active ingredient tirzepatide from Eli Lilly. It is what is known as a dual agonist: it acts on both the GLP-1 and the GIP hormone receptors. Both pathways are involved in appetite regulation, satiety and fat metabolism. In practice, this means hunger and food cravings drop noticeably more strongly for many users than with GLP-1-only injections.
The EMA approved Mounjaro for type 2 diabetes in 2022; at the end of 2023 the approval for weight management in adults with obesity or overweight plus a weight-related condition followed. In Germany the injection has been broadly available since 2025 – for both indications.
The injection is given once a week, ideally on the same weekday. Injection sites (abdomen, thigh, upper arm) should be rotated.
In the pivotal trial SURMOUNT-1, participants on the highest dose (15 mg) lost on average about 20.9 % of their body weight over 72 weeks – placebo: around 3 %. NEJM: SURMOUNT-1 (2022).
Particularly interesting is the head-to-head comparison SURMOUNT-5: tirzepatide 15 mg achieved roughly 20 % weight loss versus roughly 14 % on semaglutide 2.4 mg (Wegovy). NEJM: SURMOUNT-5 (2025). Efficacy is not everything, though – tolerability and your individual situation matter just as much.
Depending on the dose, self-payer costs are roughly 350–450 € per month. Higher doses cost more than the entry steps. Insurance reimbursement is currently the exception and has to be clarified individually.
Mounjaro is an option for adults with BMI ≥ 30 or BMI ≥ 27 plus a weight-related condition – particularly when experience with other GLP-1 injections already exists or the weight-loss target is high. The decision rests with the medical team after reviewing your history. An overview of all alternatives is available in our comparison of weight-loss injections.
In the head-to-head trial (SURMOUNT-5), tirzepatide achieved higher weight losses than semaglutide 2.4 mg. "Stronger" does not automatically mean better suited – tolerability and individual factors count as well.
Many users notice reduced hunger already in the start-up phase. Significant weight changes usually appear from week 4–8.
Zepbound is the US brand name of the same active ingredient, tirzepatide, for the weight-loss indication. In the EU the product is called Mounjaro.
Keeping the same weekday is recommended. If a dose is shifted, at least three days (72 hours) must pass between two doses.